3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
14
Neoplasms
4
Lung Neoplasms
4
Advanced Solid Tumors
3
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Thoracic Neoplasms
1
Solid Tumor, Adult
1
Solid Tumor
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Noonan Syndrome
1
Neoplasms by Site
1
Mesothelioma
1
Lung Diseases
1
KRAS p.G12C Mutant Advanced Solid Tumors
1
KRAS p, G12c Mutated /Advanced Metastatic NSCLC
1
Hereditary Sensory and Autonomic Neuropathies
1
Healthy Participants
1
Carcinoma
1
Bronchial Neoplasms
1
Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
1
Advanced Solid Tumor
1
Interventions
Gemcitabine
205
130-nm albumin-bound paclitaxel
84
Albumin-Bound Paclitaxel
57
pembrolizumab
43
Fluorouracil
41
Leucovorin
34
Oxaliplatin
33
Capecitabine
25
Nivolumab
22
Irinotecan
19
Bevacizumab
17
Paclitaxel
16
Cyclophosphamide
15
Cetuximab
15
Taxes
13
Erlotinib Hydrochloride
13
Drug Therapy
13
Carboplatin
12
irinotecan sucrosofate
11
Injections
10
Cisplatin
9
fludarabine
8
ALT-803
8
spartalizumab
7
olaparib
7
avelumab
7
Pemetrexed
7
Docetaxel
7
ruxolitinib
6
TH 302
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Pancreatic Neoplasms
×
sotorasib
×
Clear all
NCT07563738
2026-05-04
TEADCO
Orion Corporation, Orion Pharma
Phase 1/2
Recruiting
229 enrolled